Publication | Closed Access

INITIAL CLINICAL EXPERIENCE WITH I.C.I. 66.082, A NEW β‐ADRENERGIC BLOCKING AGENT, IN HYPERTENSION.

Molecular PharmacologyHypertensionCardiovascular DiseaseMedicineAntihypertensive TherapyCardiovascular PharmacologyIn HypertensionPharmacotherapyPharmacologyBlood PressureAlpha-adrenergic Pharmacology